Article thumbnail
Location of Repository

Treatment of age-related macular degeneration: focus on ranibizumab

By Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken and Peter Szurman

Abstract

Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes significant visual improvement in many patients with choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). These benefits of intravitreal ranibizumab apply to all angiographic subtypes of neovascular AMD and across all lesion sizes when the drug is injected at monthly intervals as shown in two pivotal phase III trials (ANCHOR and MARINA). The results from the PrONTO study suggest that less frequent treatment with ranibizumab through a variable dosing regimen dependent on optical coherence tomography (OCT) findings is a treatment option that results in comparably favorable visual outcomes. Currently, it is unclear whether combination therapy of ranibizumab with photodynamic therapy (PDT) provides any significant advantage over ranibizumab monotherapy (FOCUS trial); however, the combination of PDT and ranibizumab may decrease the need for frequent retreatment. This question will be addressed in the SUMMIT trial. Therapy with ranibizumab is generally very well tolerated with a low rate of seriously adverse ocular events or systemic side-effects. The advent of vascular endothelial growth factor (VEGF) inhibitors has revolutionized the therapy of neovascular AMD. Ranibizumab at the moment appears to be the most effective approved treatment for neovascular AMD

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2698673
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). 11. (Epub ahead of print).
  2. (2006). A very effective treatment for neovascular macular degeneration.
  3. (2007). An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
  4. (2006). Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
  5. (2004). Are novel drugs more risky for patients than less novel drugs?
  6. (2007). Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection.
  7. (2007). Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration.
  8. (2004). Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for metastatic colorectal cancer.
  9. (2004). Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration.
  10. (1986). Choroidal neovascularization.
  11. (2003). CNV subtype in fi rst eyes predicts severity of ARM in fellow eyes.
  12. (2007). Comparative antiproliferative and cytotoxic profi le of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol, Mar 9 (Epub ahead of print).
  13. (2004). Complications of Age-Related Macular Degeneration Prevention Trial Research Group.
  14. (2007). Current treatment of age-related macular degeneration. Optom Vis Sci,
  15. (2006). Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
  16. (2006). Effects of bevacizumab on retinal function in isolated vertebrate retina.
  17. (2006). Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).
  18. (2007). Epub ahead of print;
  19. (2006). Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfi n photodynamic therapy.
  20. (2007). for the MARINA Study Group.
  21. (2007). Full macular translocation versus photodynamic therapy with verteporfi n in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol,
  22. (2007). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand,
  23. (2007). Health Care Provider” letter January 24, 2007; available at http://www.gene.com./gene/products/information/tgr/lucentis/index.jsp.Clinical Ophthalmology 2008:2(1) 13 Ranibizumab for age-related macular degeneration
  24. (1997). Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,
  25. (1998). Identifi cation and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta,
  26. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
  27. (2002). Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report.
  28. (2003). Infl uence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epitheliumderived factor. Invest Ophthalmol Vis Sci,
  29. (1996). Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol,
  30. (1999). Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci,
  31. (2006). Intravitreal avastin: the low cost alternative to lucentis?
  32. (2007). Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
  33. (2006). Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
  34. (2007). Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol,
  35. (2007). Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
  36. (2006). Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci,
  37. (2006). Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
  38. (2006). Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
  39. (2007). Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol,
  40. (2006). Is intravitreal bevacizumab (Avastin) safe?
  41. (2000). Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev,
  42. (1996). Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.
  43. (2002). Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis,
  44. Macular photocoagulation study group.1991. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol,
  45. (2002). Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol,
  46. (2005). Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
  47. (2005). Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging,
  48. (2007). Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
  49. (2004). Pegaptanib for neovascular age-related macular degeneration.
  50. (2002). Photodynamic effects on choroidal neovascularization and physiological choroid.
  51. (2005). Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev,
  52. (2006). Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
  53. (2006). Photodynamic therapy with verteporfi n and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
  54. (2006). PIER: Year 1 FA/OCT Results in a Study of Ranibizumab (LucentisTM) for Choroidal Neovascularisation (CNV) due to Age related Macular Degeneration (AMD).
  55. (2003). Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci,
  56. (2005). Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci,
  57. (2002). Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol,
  58. (2007). Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
  59. (2006). Ranibizumab combined with verteporfi n photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol, 124:153215–42. Erratum in: Arch Ophthalmol,
  60. (2006). Ranibizumab for neovascular age-related macular degeneration.
  61. (2006). Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
  62. (2006). Ranibizumab versus verteporfi n for neovascular age-related macular degeneration.
  63. (2007). Ranibizumab, pegaptanib and bevacizumab for the treatment of age-related macular degeneration. APC/DTC Briefi ng.
  64. (2006). Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther,
  65. (1996). Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.
  66. (2005). Safety and effi cacy of intravitreal injection of ranibizumab in combination with verteporfi n PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol,
  67. (2007). Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fi elds, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol,
  68. (2006). Safety of intravitreal injection of bevacizumab in rabbit eyes.
  69. (1999). Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affi nity-matured Fab in complex with antigen.
  70. (2006). Short-term safety and effi cacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration.
  71. (2006). Supplementary Appendix to Ranibizumab for neovascular age-related macular degeneration.
  72. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twenty-four-week results of an uncontrolled open-label clinical study.
  73. (1993). The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking
  74. (2003). The biology of VEGF and its receptors.
  75. (2006). The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
  76. (2006). The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration.
  77. (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond),
  78. (2006). Tolerability and effi cacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology,
  79. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fl uid.
  80. (2007). Twelvemonth safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol, Aug 3 [Epub ahead of print].
  81. (2007). Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol,
  82. (1996). Vascular effects of photodynamic therapy.
  83. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen.
  84. (2005). Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol Pharmacol,
  85. (1998). VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
  86. (2005). Verteporfi n therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials:
  87. (2002). Verteporfi n therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.